N-terminal prohormone of brain natriuretic peptide
| natriuretic peptide B | |||||||
|---|---|---|---|---|---|---|---|
| Identifiers | |||||||
| Symbol | NPPB | ||||||
| NCBI gene | 4879 | ||||||
| HGNC | 7940 | ||||||
| OMIM | 600295 | ||||||
| RefSeq | NM_002521 | ||||||
| UniProt | P16860 | ||||||
| Other data | |||||||
| Locus | Chr. 1 p36.2 | ||||||
| |||||||
N-terminal prohormone of brain natriuretic peptide (NT-proBNP or BNPT) is a 76 amino acid long protein that is cleaved from the N-terminal end of the 108 amino acid long prohormone proBNP to release brain natriuretic peptide 32 (BNP, also known as B-type natriuretic peptide). [1][2][3]
Both BNP and NT-proBNP levels in the blood are used for screening, diagnosis of acute congestive heart failure (CHF) and may be useful to establish prognosis in heart failure, as both markers are typically higher in patients with worse outcome.[4] The plasma concentrations of both BNP and NT-proBNP are also typically increased in patients with asymptomatic or symptomatic left ventricular dysfunction and is associated with coronary artery disease, myocardial ischemia, and severity of aortic valve stenosis.[5][6][7][8][9][10]
- ^ McKie PM, Burnett JC (2016-12-06). "NT-proBNP". Journal of the American College of Cardiology. 68 (22): 2437–2439. doi:10.1016/j.jacc.2016.10.001.
- ^ Hall C (2004). "Essential biochemistry and physiology of (NT-pro)BNP". European Journal of Heart Failure. 6 (3): 257–260. doi:10.1016/j.ejheart.2003.12.015. ISSN 1879-0844.
- ^ "UpToDate". www.uptodate.com. Retrieved 2024-12-21.
- ^ Bhalla V, Willis S, Maisel AS (2004). "B-type natriuretic peptide: the level and the drug--partners in the diagnosis of congestive heart failure". Congestive Heart Failure. 10 (1 Suppl 1): 3–27. doi:10.1111/j.1527-5299.2004.03310.x. PMID 14872150.
- ^ Atisha D, Bhalla MA, Morrison LK, Felicio L, Clopton P, Gardetto N, et al. (September 2004). "A prospective study in search of an optimal B-natriuretic peptide level to screen patients for cardiac dysfunction". American Heart Journal. 148 (3): 518–523. doi:10.1016/j.ahj.2004.03.014. PMID 15389242.
- ^ Nakamura T, Sakamoto K, Yamano T, Kikkawa M, Zen K, Hikosaka T, et al. (May 2002). "Increased plasma brain natriuretic peptide level as a guide for silent myocardial ischemia in patients with non-obstructive hypertrophic cardiomyopathy". Journal of the American College of Cardiology. 39 (10): 1657–1663. doi:10.1016/s0735-1097(02)01813-2. PMID 12020494.
- ^ Talwar S, Squire IB, Downie PF, Davies JE, Ng LL (October 2000). "Plasma N terminal pro-brain natriuretic peptide and cardiotrophin 1 are raised in unstable angina". Heart. 84 (4): 421–424. doi:10.1136/heart.84.4.421. PMC 1729429. PMID 10995414.
- ^ Kim H, Yang DH, Park Y, Han J, Lee H, Kang H, et al. (November 2006). "Incremental prognostic value of C-reactive protein and N-terminal proB-type natriuretic peptide in acute coronary syndrome". Circulation Journal. 70 (11): 1379–1384. doi:10.1253/circj.70.1379. PMID 17062957.
- ^ Ruwald MH, Goetze JP, Bech J, Nielsen OW, Madsen BK, Nielsen LB, et al. (January 2014). "NT-ProBNP independently predicts long-term mortality in patients admitted for coronary angiography". Angiology. 65 (1): 31–36. doi:10.1177/0003319712462758. PMID 23070682. S2CID 33475819.
- ^ Hadziselimovic E, Greve AM, Sajadieh A, Olsen MH, Kesäniemi YA, Nienaber CA, et al. (April 2022). "Association of Annual N-Terminal Pro-Brain Natriuretic Peptide Measurements With Clinical Events in Patients With Asymptomatic Nonsevere Aortic Stenosis: A Post Hoc Substudy of the SEAS Trial". JAMA Cardiology. 7 (4): 435–444. doi:10.1001/jamacardio.2021.5916. PMC 8851368. PMID 35171199.